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The skin secretions ofNeotropical phyllomedusine leaf frogs have proven to be a rich source of biologically active peptides, including
antimicrobials.Themajor families of antimicrobial peptides (AMPs) reported are the dermaseptins and phylloseptins and theminor
families are the dermatoxins, phylloxins, plasticins, distinctins, and medusins. Here, we report a novel AMP of 10 amino acid
residues (LRPAILVRIKamide), named balteatide, from the skin secretion of wild Peruvian purple-sided leaf frogs, Phyllomedusa
baltea. Balteatide was found to exhibit a 90% sequence identity with sauvatide, a potentmyotropic peptide from the skin secretion of
Phyllomedusa sauvagei. However, despite both peptides exhibiting only a single amino acid difference (I/T at position 9), sauvatide
is devoid of antimicrobial activity and balteatide is devoid of myotropic activity. Balteatide was found to have differential activity
against the Gram-positive bacterium, Staphylococcus aureus; the Gram-negative bacterium, Escherichia coli; and the yeast, Candida
albicans, and unusual for phyllomedusine frog skin AMPs, was most potent (MIC 32mg/L) against the yeast. Balteatide was also
devoid of haemolytic activity up to concentrations of 512mg/L. Phyllomedusine frog skin secretions thus continue to provide novel
AMPs, some of which may provide templates for the rational design of new classes of anti-infective therapeutics.
1. Introduction
The development of novel classes of anti-infective therapeu-
tics has become an imperative within the pharmaceutical
industry as pathogens continue to become resistant to all
currently available antibiotics on a global scale [1–3]. Pep-
tides, although generally shunned by the industry as drug
candidates, have attractedmuch research attention as current
evidence suggests that they are of ancient origin and occur as
a component of front-line defence againstmicrobial infection
within the innate immune systems of both invertebrates and
vertebrates and they even occur in plant tissues [2, 3].
More than 500 different antimicrobial peptides (AMPs)
have been reported from diverse natural sources and the
majority of those present in contemporary online databases
are of amphibian skin origin [4]. One of the most important
attributes of these amphibian skin AMPs is their broad
spectrum of activity against bacteria, fungi, viruses, and
protozoa [5, 6]. Structure/activity studies have revealed
some common features of this class of peptides. Most are
cationic and amphipathic containing a significant number
of positively charged and hydrophobic amino acid residues;
often the C-terminus is amidated effectively removing a
membrane-repelling negative charge and replacing thiswith a
hydrophobicmembrane-interacting group; those that display
antifungal activity often contain a high proportion of polar
neutral amino acid residues [7–9].The general mechanism of
action of these AMPs is thought to involve initial electrostatic
binding to the outer surfaces of cell membranes and then
insertion of aggregates into the membranes to form pores
through which the passage of ions and water is unregulated,
leading to cell lysis [10]. Although there are major obstacles
to the use of AMPs systemically, they appear to be effective
for topical use as they have been shown to be capable of
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penetrating the stratum corneum and hence could be used
to prevent infection of wounds [11]. The amphibians would
appear to have evolved these AMPs for such a topical anti-
infection role.
The Central and South American leaf frogs of the sub-
family Phyllomedusinae have been found to possess some of
the most molecularly complex and biologically potent skin
secretions of any amphibians [12]. For these reasons and
because of their species diversity and relative abundance,
they have been widely studied for several decades [13]. Here,
we report the presence of a novel AMP, named balteatide,
from the skin secretions of wild specimens of the hith-
erto unstudied Peruvian species, the purple-sided leaf frog,
Phyllomedusa baltea. Balteatide is a C-terminally amidated
decapeptide, LRPAILVRIKamide, which displays particular
potency against the pathogenic yeast, Candida albicans.
2. Methods and Materials
2.1. Acquisition of Phyllomedusa baltea Skin Secretion. Ly-
ophilised skin secretion (40mg dry weight), from wild
Peruvian specimens of Phyllomedusa baltea, was obtained
fromPeruBiotechE.I.R.L. Skin secretionswere obtained from
the dorsal surfaces of frogs by gentle transdermal electrical
stimulation. Briefly, the moistened skin was stimulated by
platinum electrodes (6VDC; 4ms pulse-width; 50Hz) for
two periods of 20 s duration following which the secretion
was washed from the skin using deionised water, snap-frozen
in liquid nitrogen, and lyophilised. Lyophilisate was stored at
−20∘C prior to transportation and analysis.
2.2. Isolation and Structural Characterisation of Antimicrobial
Activity from Lyophilised P. baltea Skin Secretion. A 5mg
sample of lyophilised P. baltea skin secretion was dissolved
in 0.5mL of trifluoroacetic acid (TFA)/water (0.05/99.95;
v/v) and clarified by centrifugation (1100×g; 5min). The
supernatant was decanted and subjected to reverse-phase
HPLC fractionation using a Waters HPLC system fitted with
an analytical column (Phenomenex C-5; 250mm × 4.6mm).
Thiswas elutedwith a linear gradient formed fromTFA/water
(0.05/99.95; v/v) to TFA/water/acetonitrile (0.05/19.95/80.0;
v/v/v) in 240min at a flow rate of 1mL/min.The column efflu-
ent was continuously monitored spectrophotometrically at 𝜆
214 nm and fractions (1mL) were collected automatically at
minute intervals. Samples (100 𝜇L) were removed from each
fraction, lyophilised, and stored at −20∘C prior to subjecting
to antimicrobial assays. The molecular masses of peptides in
each fraction displaying antimicrobial activity were analysed
using matrix-assisted laser desorption/ionisation, time-of-
flight mass spectrometry (MALDI-TOF MS) on a linear
time-of-flight Voyager DE mass spectrometer (Perseptive
Biosystems, MA, USA) in positive detection mode using 𝛼-
cyano-4-hydroxycinnamic acid as thematrix.The amino acid
sequence of the major resolved peptide in the antimicrobially
active fraction was determined by MS/MS fragmentation
sequencing using a LCQ-Fleet electrospray ion-trap mass
spectrometer.
2.3. Antimicrobial Activity Screening Assays. Standard model
nonpathogenic bacterial and yeast strains were used in these
antimicrobial activity screening assays.Microorganisms used
were the Gram-positive bacterium, Staphylococcus aureus
(NCTC 10788); the Gram-negative bacterium, Escherichia
coli (NCTC 10418); and the yeast, Candida albicans (NCPF
1467). The antimicrobial activity of peptides in reverse phase
HPLC fractions of skin secretion was initially evaluated using
inhibition zone assays on Luria-Bertani (LB) agarose plates
[14]. To assess microbicidal effects, the lyophilised samples
of each chromatographic fraction, following reconstitution in
phosphate-buffered saline (PBS, pH 7.4 - 200 𝜇L), were added
to separate 2mm diameter holes that had been punched in
the surface of the agar plate. The plates were then incubated
at 37∘C overnight.
2.4. Molecular Cloning of the Novel AMP Biosynthetic
Precursor-Encoding cDNA from a P. baltea Skin Secretion-
Derived cDNA Library. A second 5mg sample of lyophilised
P. baltea skin secretion was dissolved in 1mL of cell
lysis/mRNA protection buffer supplied by Dynal Biotech,
UK, and polyadenylated mRNA was isolated by magnetic
oligo-dT beads as described by the manufacturer (Dynal
Biotech, UK). The isolated mRNA was subjected to 5󸀠- and
3󸀠-rapid amplification of cDNA ends (RACE) procedures
to obtain full-length AMP biosynthetic precursor nucleic
acid sequence data using a SMART-RACE kit (Clontech,
UK) essentially as described by the manufacturer. Briefly,
the 3󸀠-RACE reactions employed a nested universal (NUP)
primer (supplied with the kit) and a sense primer (S: 5󸀠-
TIMGICCIGCIATHYTIGT-3󸀠) (I = deoxyinosine, M = A/C,
H = A/T/C, and Y = C/T) that was complementary to the
N-terminal amino acid sequence, L/I-R-P-A-L/I-L/I-V-, of
the N-terminal region of balteatide. The 3󸀠-RACE reactions
were purified and cloned using a pGEM-T vector system
(Promega Corporation) and sequenced using an ABI 3100
automated sequencer.The sequence data obtained from these
3󸀠-RACE products were used to design a specific antisense
primer (AS: 5󸀠-GTGCTCCTCAGAGCTATGACTT-3󸀠) to a
conserved site within the 3󸀠-nontranslated region of the
balteatide-encoding transcript. 5󸀠-RACE was carried out
using this specific primer in conjunctionwith theNUPRACE
primer and resultant products were purified, cloned, and
sequenced.
2.5. Peptide Synthesis and Purification. Both balteatide and
its structural homologue, sauvatide, from Phyllomedusa
sauvagei skin secretion [15], were synthesised by solid phase
methodology using Rink amide resin and standard Fmoc
chemistry, by means of an automated PS3 peptide synthesiser
(Protein Technologies, USA), followed by deprotection and
cleavage from the resin. Each synthetic peptide was analysed
by both reverse phase HPLC and MALDI-TOF mass spec-
trometry to establish both degree of purity and authenticity
of structure.
2.6. Minimal Inhibitory Concentration (MIC) Antimicro-
bial Assays. Minimal inhibitory concentrations (MICs) for
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synthetic peptides, balteatide, and sauvatide were assessed
against the model strains of Gram-positive bacteria, Gram-
negative bacteria, and yeast, used before for initial qualitative
zonal growth inhibition assays. Each model microorganism
was initially incubated in Mueller-Hinton Broth (MHB) for
16–20 h. Upon achieving their respective logarithmic growth
phases, as measured by the optical density (OD) of media at
550 nm, the cultures were diluted to 1 × 106 colony-forming
units (cfu)/mL for the bacteria and to 5 × 105 cfu/mL for the
yeast. Samples of these were then added to 96-well microtiter
plates and mixed with the peptides at a range of concentra-
tions (1–512mg/L). Positive controls were included using the
cytolytic bee venom peptide, melittin, and ampicillin, in a
similar concentration range to the test peptides. After 24 h
incubation, the OD of each well was measured at 550 nm
using a Synergy HT plate reader (BioTek, USA), and the data
were analysed using Graph Pad Prism 5 software. The MIC
was defined as the minimum concentration of peptide that
resulted in an OD that was the same as the negative control.
2.7. Haemolysis Assay. A 2% (v/v) suspension of red blood
cells was prepared from defibrinated horse blood (TCS Bio-
sciences Ltd., UK). Peptide solutions at different concentra-
tions were prepared as described in the previous section. Red
blood cell suspension samples (200 𝜇L) were incubated with
a range of peptide concentrations (1–512mg/L) as employed
for antimicrobial MIC assays, at 37∘C for 60min. Lysis of red
cells was assessed by measurement of optical density at 𝜆 =
550 nm using an ELISA plate reader (Biolise BioTek EL808).
Negative controls employed consisted of a 2% (v/v) red cell
suspension and sodium phosphate-buffered saline (PBS) in
equal volumes and positive controls consisted of a 2% (v/v)
red cell suspension and an equal volume of PBS containing
2% (v/v) of the nonionic detergent, Triton X-100 (Sigma-
Aldrich).
2.8. Rat Urinary Bladder Smooth Muscle Bioassay. Male
Wistar rats (250–300 g) were euthanised by carbon dioxide
asphyxiation followed by cervical dislocation under appro-
priate UK animal licences and in keeping with institutional
ethical guidelines. The rats were placed dorsal surface down
and the abdomen was opened by means of an incision
along the midventral line and subcutaneous fat was carefully
dissected. The exposed urinary bladder was removed from
each rat, emptied of urine, and placed in ice-cold Krebs solu-
tion (118mM NaCl, 4.7mM KCl, 25mM NaHCO
3
, 1.15mM
NaH
2
PO
4
, 2.5mM CaCl
2
, 1.1mM MgCl
2
, and 5.6mM glu-
cose), equilibrated with 95% O
2
, 5% CO
2
. Muscle strips,
2mm × 10mm, were dissected from the bladder under a
dissectionmicroscope.These were tied at each endwith a fine
silk ligature (0.2mm) with one end subsequently attached to
a fixed pin and the other to a transducer in a 2mL organ
bath containing Krebs solution at 37∘C flowing at 2mL/min
with constant bubbling of 95% O
2
, 5% CO
2
. After a 20min
equilibration period, muscle strips were tested for viability
using 60mM KCl. Peptide solutions, ranging in concentra-
tion from 10−11 to 10−5M,weremade inKrebs buffer andwere
used to construct dose-response curves. These were added
to the bladder muscle strips in increasing concentrations
with 5min washes and 5min equilibration periods between
each dose. Each peptide concentration was applied to a
minimum of five muscle strips. Changes in tension of the
bladder muscle strips were recorded and amplified through
pressure transducers connected to a PowerLab System (AD
Instruments Pty Ltd.). Data were analysed to obtain themean
and standard error of responses by Student’s t-test and dose-
response curves were constructed using a best-fit algorithm
through the data analysis package provided. Responses were
plotted as percentages of maximal contraction against final
molar concentrations of peptide present in the organ baths.
3. Results
3.1. Identification and Structural Analysis of Balteatide.
Reverse-phase HPLC fractionation of P. baltea skin secretion
resulted in a complex chromatogram. The elution posi-
tion/retention time of the AMP-containing fraction (number
114), established by zonal growth inhibition assay, is indicated
by an arrow (Figure 1(a)). MALDI-TOF analysis of a sample
from this fraction revealed the presence of a major, singly
charged peptide (M + H)+ of m/z 1178.5 (data not shown).
Subsequent infusion of this fraction into an LCQ-Fleet
electrospray ion-trap mass spectrometer and trapping of the
predominant doubly charged (M + 2H)2+ ion at m/z 589.5,
followed byMS/MS fragmentation, resulted in the generation
of a sequence by the de novo sequencing software: L/I-R-P-
A-L/I-L/I-V-R-I/L-K.amide (Figure 1(b)). This novel peptide
was named balteatide, reflecting its species of origin and
its structural similarity to a previously reported myotropic
peptide named sauvatide, from the skin secretion of Phyl-
lomedusa sauvagei [15].
3.2. Molecular Cloning of the cDNA Encoding the Biosyn-
thetic Precursor of Balteatide. A single cDNA encoding the
biosynthetic precursor of balteatide was consistently cloned
from the skin secretion-derived cDNA library using the
RACE protocol described (Figure 2(a)). In terms of the
balteatide precursor protein architecture, the N-terminal 22
amino acid residues encoded a putative signal peptide and
the following 26 amino acid residues constituted an acidic
amino acid residue-rich spacer peptide domain containing
two classical-Lys-Arg-(-K-R-) propeptide convertase cleav-
age sites, the second of which immediately flanked the N-
terminus of balteatide. The presence of an amide moiety
on the C-terminal Lys (K) residue was implied by the
presence of a strategically located Gly (G) residue that acts
as an amide donor through the action of amidating enzyme
complex.The C-terminal extension sequence, -KGK, was not
present on the mature peptide identified in skin secretion
and is presumably enzymatically removed after translation.
The successful cloning of the balteatide precursor-encoding
cDNA also facilitated resolution of the isobaric L/I residue
ambiguity following MS/MS fragmentation sequencing and
established the presence of L at position 1, I at position 5, L at
position 6, and I at position 9 (Figures 2(a) and 2(b)). BLAST
analysis of this sequence, using the National Center for
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Figure 1: (a) Region of reverse phase HPLC chromatogram of Phyllomedusa baltea skin secretion indicating the absorbance peak
corresponding to balteatide (arrow). The 𝑌-axis represents the relative absorbance at 𝜆 214 nm and the 𝑋-axis represents the retention time
in minutes. (b) Predicted 𝑏- and 𝑦-ion series (singly, doubly, and triply charged) of balteatide. Ions observed in MS/MS spectra are indicated
in bold typeface and are underlined.
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ATGGCTTTTT TGAAGAAATC CCTTTTCCTT GTCCTGTTCC TTGGATTAGT
TACCGAAAAA ACTTCTTTAG GGAAAAGGAA CAGGACAAGG AACCTAATCA
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CCCGCTATTC TTGTTCGCAT TAAAGGAAAA GGAAAATGAG AAAATGTGAC
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AAGTCATAGC TCTGAGGAGC ACTATGTATA ACTGTGCACA AAATATATTA
TTCAGTATCG AGACTCCTCG TGATACATAT TGACACGTGT TTTATATAAT
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Figure 2: (a) Nucleotide and translated open-reading frame amino acid sequence of the sense strand of the cloned cDNA encoding the
biosynthetic precursor of balteatide.Theputative signal peptide is double-underlined and themature balteatide sequence is single-underlined.
The stop codon is indicated with an asterisk. (b) Domain architecture of the balteatide precursor. Residues 1–22 constitute the putative signal
peptide. Residues 23–48 constitute the acidic spacer peptide region typified by classical-KR-(-Lys-Arg-) propeptide convertase processing sites
(italicised and in bold typeface). The single copy of mature balteatide (residues 49–58) is underlined and in bold typeface and the C-terminal
glycyl (G59) residue that donates the amide moiety is indicated in brackets.
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ATGGCTTTTTTGAAGAAATCCCTTTTCCTTGTCCTGTTCCTTGGATTAGT
ATGGATATCCTGAAGAAATCTCTTTTCCTCATCCTGTTCCTTGGATTAGT
TTCCATTTCCTTCTGTGTTGAAGAGAAAAGACAGGATGACGATGAGGCTA
TTCCATTTCCTTCTGTGATGGAGAGAAAAGACAAGATGACGACGAGGCTA
ATGAGAGCGAGGAAAAGAAAGAAATACATGAAGTGGAGAAAAGATTGCGG
ATGAGAGTGAGGAAAAGAAAGAAATTCATGAAGTGGAGAAAAGATTGCGG
CCCGCTATTCTTGTTCGCATTAAAGGAAAAGGAAAATGAGAAAATGTGAC
CCCGCTATTCTTGTTCGCACTAAAGGAAAAGGAAAATGAGAAAATGTGAT
AAGTCATAGCTCTGAGGAGCACTATGTAT- - - -AACTGTGCACAAAATAT
AAGTCATAGTTCTGAGGAGCATTATGTATCCATAATTGTGCA CA AAATAT
ATTAAAGCAAATTAAGCAAACAAAAAAAAAAAAAAAAAAAAA
ATTAAATCAAATAAAGCAAACAAAAAAAAAAAAAAAAAAAAA
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Figure 3: (a) Alignment of the nucleotide sequences of cDNAs encoding balteatide and sauvatide precursors. Identical bases in both are
back-shaded in black. (b) Alignment of translated open-reading frame amino acid sequences of balteatide and sauvatide precursors. Sites of
amino acid residue differences are indicated by asterisks.
Table 1: Mean inhibitory concentrations (MICs) of each antimicrobial agent against the three model test microorganisms employed.
MICs (mg/L and 𝜇M)
E. coli S. aureus C. albicans
Balteatide 128mg/L (109 𝜇M) >512mg/L (435𝜇M) 32mg/L (27𝜇M)
Sauvatide >512mg/L (439𝜇M) 512mg/L (439 𝜇M) 512mg/L (439𝜇M)
Melittin 16mg/L (6𝜇M) 8mg/L (3𝜇M) 8mg/L (3 𝜇M)
Ampicillin 8mg/L (23𝜇M) 0.0625mg/L (0.2 𝜇M) NE
NE: not effective.
Biotechnological Information (NCBI) online portal, revealed
that the balteatide precursor displayed a 92% nucleotide
sequence and a 90% amino acid sequence identity to the
sauvatide precursor from the skin of the waxy monkey frog,
Phyllomedusa sauvagei (Figures 3(a) and 3(b)). However, the
respective mature peptides, balteatide and sauvatide, only
differed in a single amino acid (I/T) at position 9.
3.3. Antimicrobial MIC Assays. The data derived from the
parallel MIC determination experiments, using synthetic
balteatide and sauvatide, are illustrated in Figures 4(a)–4(c).
Balteatide was moderately active against E. coli with an
MIC of 128mg/L (109 𝜇M) and sauvatide was essentially
ineffective at the highest concentration tested (512mg/L;
439 𝜇M) (Figure 4(a)). Balteatide was essentially ineffective
against S. aureus while sauvatide exhibited an MIC of
512mg/L (439 𝜇M) (Figure 4(b)). The greatest difference in
antimicrobial potency was observed with C. albicans against
which balteatide exhibited an MIC of 32mg/L (27𝜇M) com-
pared to that of sauvatide (512mg/L; 439 𝜇M) (Figure 4(c)).
All quantitative data, including the MICs obtained for the
positive controls, are summarised in Table 1.
3.4. Haemolytic Activity Assay. Both peptides were found to
possess little haemolytic activity (less than 8%) at the highest
concentrations tested (512mg/L) (Figure 5). At the effective
MICs for balteatide against E. coli (128mg/L) and C. albicans
(32mg/L), the level of haemolytic activity was negligible.
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Figure 4: Dose-response curves of synthetic balteatide (󳵳) and sauvatide (×) with the three model test microorganisms: (a) Escherichia coli
(NCTC 10418), (b) Staphylococcus aureus (NCTC 10788), and (c) Candida albicans (NCPF 1467).
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Figure 5: Haemolytic activity of synthetic balteatide (Q) and
sauvatide (×), respectively. Positive (◼) and negative (Q) controls are
included for reference.
3.5. Rat Urinary Bladder Smooth Muscle Pharmacology. In
this bioassay, the activities of both peptides were quite
disparate despite their highly conserved primary structures
(Figure 6). Sauvatide was a potent myotropic agent in rat
urinary bladder smooth muscle with an EC
50
of 4.7 nM
(4.7 × 10−9M). In contrast, balteatide was inactive in this
smooth muscle preparation at concentrations up to 10𝜇M (1
× 10−5M).
4. Discussion
The spread of microbial resistance is leading to a pandemic
in untreatable or difficult-to-treat infections of both humans
and livestock [1–3, 16]. This resistance poses a massive threat
to human health and food supplies and it is imperative
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Figure 6: Dose-response curves of sauvatide (◼) and balteatide (󳵳)
on rat bladder smooth muscle preparations. Each point represents
the mean and standard error of six determinations.
that both academic and industrial bioscientists join forces
in the quest for novel molecular solutions to this rapidly
growing global problem [17]. Our increasing knowledge
and database of naturally occurring antimicrobial peptides,
whose origins in the biosphere are undoubtedly ancient,
provide one possible avenue to pursue towards the goal of
discovering or developing novel anti-infection therapeutics
[2, 3, 18]. AMPs are now known to constitute a fundamental
component of innate immunity/molecular defence across
most forms of life, including bacteria [5–11]. AMPs tend to be
potent and broad spectrum in action and can kill both Gram-
negative and Gram-positive bacteria, including those strains
which are resistant to conventional antibiotics. Amphibian
skin secretions appear to be one of the richest natural sources
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of diverse antimicrobial peptides [12, 13, 19]. These peptides
have been found to have efficacy againstmanyGram-negative
and Gram-positive bacteria, fungi, protozoans, and some
viruses, including HIV. They are thought to be particularly
abundant in frog skin secretions as a defence against surface
microbial colonisation, a consequence of both life forms
being particularly abundant in the same biotopes [5, 6, 20, 21].
Here, we have described the identification and structural
characterisation of a novel AMP, named balteatide, from
the skin secretion of wild Peruvian purple-sided leaf frogs,
Phyllomedusa baltea. This C-terminally amidated decapep-
tide is representative of a novel class of AMPs, a group of
peptides which are particularly abundant and structurally
diverse in phyllomedusine leaf frogs [12, 13]. This is the
smallest of such peptides reported thus far from this source.
It is generally agreed that amphibian skin AMPs, in common
with those from many other sources, act in a membranolytic
fashion to destroy the integrity of microorganisms [5–11].
To achieve this biological endpoint, there appears to be an
optimumpeptide chain length required to effectively span the
membrane and this is considered to be considerably longer
than ten residues [5–11, 21]. However, in keeping with some
recent evidence that suggests that certain AMPs may act
through other targets, some of which are intracellular [5–
11, 20, 21], the possibility exists that balteatide may have such
an alternative target. Its spectrum of antimicrobial action
was found to be unusual in that it was most potent at
inhibiting the growth of the yeast, C. albicans, less potent
against the Gram-negative bacterium, E. coli, and least
effective against the Gram-positive bacterium, S. aureus.
Most AMPs are cationic and amphipathic in nature and are
thought to initially bind electrostatically to the negatively
charged phospholipids within prokaryotic membranes. A
typical spectrum of decreasing efficacy for amphibian skin
AMPs would be S. aureus > E. coli > C. albicans. Eukaryotic
membranes, such as those in the yeast, C. albicans, are more
resistant to the effects of these AMPs as a consequence
of membrane compositional differences that provide a less
anionic surface for cationic peptide interaction [6–11, 19, 22].
The apparent degree of specificity exhibited by balteatide for
the eukaryotic test microorganism in the present study may
imply a nonmembranolytic mode of action. This suggestion
is provided with some credence by the lack of haemolytic
activity exhibited by balteatide in the present study. Although
many other amphibian skinAMPsmay have higher potencies
and spectra of actions, the apparent high degree of specificity
of balteatide for the yeast demonstrated here is a unique
attribute among these. Thus the preliminary observations
reported here may provide a rationale for instigating more
in-depth studies on balteatide with respect to its mode of
action and molecular target. If this peptide should prove, in
further studies, to be active against other types of fungi, it
could represent the lead compound for the development of
a novel class of antifungal therapeutic. If not, then it could be
therapeutically useful againstC. albicans infections which are
in themselves sufficiently widespread and troublesome.
Following unequivocal establishment of the primary
structure of balteatide, an NCBI BLAST search was
performed which indicated that it was 90% identical to
the myotropic peptide, sauvatide, previously isolated from
the skin secretion of the waxy monkey frog, Phyllomedusa
sauvagei [15]. Both peptides differed by just one amino
acid residue at position 9 (Ile (I) in balteatide and Thr (T)
in sauvatide). For this reason, sauvatide was chemically
synthesised and subjected to antimicrobial and urinary
bladder smooth muscle bioassays in parallel with balteatide.
Sauvatide displayed little or no antimicrobial activity
at the concentrations tested and was considerably less
effective than balteatide in inhibiting the growth of C.
albicans (439 𝜇M compared to 27 𝜇M). However, in the
rat urinary bladder smooth muscle bioassay, sauvatide
contracted the preparation with an EC
50
of 4.7 nM (4.7
× 10−9M) and balteatide was found to be completely
ineffective up to a concentration of 10 𝜇M (1 × 10−5M).
These radical discrepancies in biological activities were
surprising in view of the high degree of structural similarity
between both peptides. The amino acid residue at position
9 thus appeared to be an essential determinant for both
bioactivities. The EC
50
value obtained for sauvatide in the
smooth muscle assay is of an appropriate magnitude for a
highly specific interaction with a discrete target receptor
and this interaction appears from the current data to be
highly dependent on the presence of a hydrophilic Thr
residue at position 9 in the peptide chain. Substitution of
this site with a hydrophobic Ile residue completely abolishes
this activity. In contrast, this single hydrophobic Ile residue
at this site appears to significantly enhance the peptides
growth inhibitory action on the yeast. Many studies relating
to studying the primary structural diversity in amphibian
skin peptide families are considered mundane, but the
current data illustrate quite unequivocally that even single
residue changes in decapeptides can drastically alter their
biological targeting and hence pharmacological profiles.
Thus elucidation of the finer structural features of naturally
occurring peptide families and screening for biological
actions can often provide invaluable information about
their structure/function requirements. When constructing
a combinatorial library of a core lead peptide structure
for drug development endpoints, this information could
potentially provide prior warning about potential side effects
and explanations for subsequently observed off-target effects.
Many studies on the plethora of bradykinins and related
peptides found in amphibian skin have previously illustrated
this phenomenon as some single amino acid substitutions
in the core nonapeptide sequence and short extensions to
N- and C-terminals can change the ligand from a receptor
agonist to antagonist [23–26].
In conclusion, the study of the structural diversity within
discrete families of natural bioactive peptides, particularly
those that are homologues of endogenous mammalian reg-
ulatory peptides, can provide libraries of unique agonists and
antagonists for exploring the structure/activity requirements
of endogenous receptors as an aid to rational analogue design.
In addition, as many of the structural modifications observed
in discrete members of these natural peptide families are
counterintuitive, they havemuch to teach the pharmaceutical
peptide engineer about peptide-based drug design. The
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targeting of sauvatide to putative receptors in urinary bladder
smooth muscle and the effect of balteatide on inhibition
of the growth of pathogenic yeast elegantly illustrate these
suggestions and open up opportunities for further studies on
both peptides as leads for both therapeutic applications.
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